← Back to headlines
J.P. Morgan Raises Novo Nordisk Price Target on Strong Ozempic and Wegovy Sales
J.P. Morgan analysts upgraded their price target for Novo Nordisk, citing robust sales performance and market demand for its blockbuster weight-loss and diabetes drugs, Ozempic and Wegovy.
Sources
Showing 0 of 1 sources
No articles available in your preferred languages.
1 article available in other languages below.
